Parkinson's Disease and Associated Cancer Risks

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterised by the loss of dopaminergic neurons in the substantia nigra and the accumulation of α-synuclein aggregates. Beyond its cardinal motor manifestations, PD exhibits intriguing epidemiological relationships with various cancers. Numerous population studies report an overall reduced incidence of several malignancies in individuals with PD, suggesting potential protective mechanisms. Conversely, elevated risks have been observed for melanoma and certain hormone‐related tumours, pointing to shared genetic and molecular pathways. Underlying mechanisms may include dysregulated protein degradation, mitochondrial dysfunction, oxidative stress and chronic neuroinflammation—factors implicated both in neuronal death and tumourigenesis. Key PD‐related genes such as PARK2 (parkin) and SNCA (α-synuclein) have been found to influence cell cycle control, apoptosis and DNA repair in non-neuronal tissues, while pleiotropic genetic variants may modulate risk across phenotypes. Understanding these interconnections offers prospects for refined risk stratification, biomarker discovery and the repurposing of oncology agents in neuroprotective strategies. As research continues to delineate convergent pathways, a nuanced view of PD and cancer comorbidity can inform both clinical surveillance and therapeutic innovation on a global scale.

Research from Nature Portfolio

Recent studies elucidate how parkin, an E3 ubiquitin ligase encoded by PARK2, regulates tumour biology. It has been shown that parkin directly targets hypoxia-inducible factor 1α (HIF-1α) for ubiquitination and proteasomal degradation, thereby suppressing metastatic potential in breast cancer models. Specific lysine residues on HIF-1α are critical for parkin-mediated ubiquitination, and cancer-associated parkin mutations abolish this tumour-suppressive activity. The inverse correlation between parkin expression and HIF-1α levels in clinical specimens underscores a mechanistic link between familial PD genes and oncogenic pathways, offering a paradigm for how neurodegenerative predisposition factors may concurrently modulate cancer risk.

Parkinson's Disease and Associated Cancer Risks publication trend

The graph below shows the total number of articles in parkinson's disease and associated cancer risks across all publications each year (not limited to Nature Index journals).

Technical terms

E3 ubiquitin ligase: An enzyme that catalyses the transfer of ubiquitin to substrate proteins, marking them for degradation by the proteasome.

Hypoxia-inducible factor 1α (HIF-1α): A transcription factor stabilised under low oxygen conditions, promoting angiogenesis and metabolic adaptation in tumours.

Polygenic risk score (PRS): A composite measure of genetic liability for a trait, calculated by summing risk alleles weighted by their effect sizes across the genome.

Cox proportional-hazards regression: A statistical method used in survival analysis to estimate the hazard ratio for an event, accounting for multiple covariates.

Pleiotropy: The phenomenon whereby a single gene or genetic variant influences multiple distinct phenotypic traits.

References

1. Longitudinal study of the inverse relationship between Parkinson’s disease and cancer in Korea. npj Parkinson's Disease (2023).
2. Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers. Movement Disorders (2023).
3. Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression. Nature Communications (2017).